linjc16/ctgov huggingface dataset:
Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.

Study Overview
=================
Brief Summary
-----------------
Hand and foot skin diseases, such as dermatitis and psoriasis, that do not respond to topical creams can be treated with ultraviolet light therapy. Topical psoralen plus ultraviolet A (PUVA) is commonly used to treat these conditions, but requires additional time for the hands and feet to soak in psoralens before the light treatment. Newer narrowband ultraviolet B (NBUVB) units have become available which allow for light treatment without soaking first. The purpose of this study is to determine if NBUVB is as effective as PUVA for hand and foot skin diseases.

Official Title
-----------------
A Randomized Controlled Trial of Narrowband Ultraviolet B vs Topical Psoralen Plus Ultraviolet A Photochemotherapy for Hand and Foot Dermatoses

Conditions
-----------------
Dermatitis, Psoriasis

Intervention / Treatment
-----------------
* Procedure: Narrowband Ultraviolet B (TL-01UVB) Therapy
* Procedure: Topical Psoralen plus ultraviolet A (PUVA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bilateral hand or foot skin disease (dermatitis, psoriasis, etc.) with symmetric distribution and severity. Exclusion Criteria: Age <18 years Pregnancy Liver disease Kidney disease History of skin cancer Phototherapy or systemic therapy for the skin condition in the preceding 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Narrowband Ultraviolet B (TL-01UVB) Therapy<br>treatments - 3x weekly for 15 months | Procedure: Narrowband Ultraviolet B (TL-01UVB) Therapy<br> <br> |
| Active Comparator: Topical Psoralen plus ultraviolet A (PUVA)<br>Treatments - 3x weekly for 15 months | Procedure: Topical Psoralen plus ultraviolet A (PUVA)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of treatments required to reach clearance |  | Baseline to 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in symptom score (erythema, scaling/hyperkeratosis, papular/vesicular eruption, and fissures) |  | Baseline to 15 months | 
| Change in global score |  | Baseline to 15 months | 
| Number of patients reaching clearance |  | Baseline to 15 months | 
| Adverse effects |  | Baseline to 15 months | 
| Number of days in remission |  | Baseline to 15 months |
Biomarkers in Patients With Advanced Rhabdomyosarcoma

Study Overview
=================
Brief Summary
-----------------
This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. To investigate whether the expression of a subset of proteins (by immunohistochemistry), known to be Involved in the paired box (Pax)3, Pax7, and Patched-1 neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar and embryonal rhabdomyosarcomas. OUTLINE: Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.

Official Title
-----------------
Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas

Conditions
-----------------
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma

Intervention / Treatment
-----------------
* Other: Laboratory Biomarker Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 8 tissue microarrays (TMA) slides of the following diseases available: Alveolar rhabdomyosarcoma Embryonal rhabdomyosarcoma Anaplastic rhabdomyosarcoma
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-Correlative (biomarker analysis)<br>Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis. | Other: Laboratory Biomarker Analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma |  | 1 month |
Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition

Study Overview
=================
Brief Summary
-----------------
Evaluate the feasability to determine the difference of tumoral metabolism before and after artificial nutrition.

Detailed Description
-----------------
Evaluation of the feasability to determine the difference of tumoral metabolism before and after artificial nutrition. This activity will be measured with TEP/TDM 18F-FDG

Official Title
-----------------
Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition Assessed by F-FDG Petscan

Conditions
-----------------
Head and Neck Cancer, Oesophageal Cancer

Intervention / Treatment
-----------------
* Device: PET/TDM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: VADS cancer or oesophageal cancer Evaluation by 18F-FDG PET denutrition with weight loss of 5% Artificial nutrition ECOG<2 Exclusion Criteria: Treatment by chemotherapy, surgery unless 2 months Treatment by radiotherapy unless 4 months Capillar glycemia >12mmol/l during the PET

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: PET/TDM<br>Evaluation by PET/TDM at 2 times | Device: PET/TDM<br>* Evaluation of nutrition absorption by TEP/TDM<br>* Other names: Parenteral or enteral nutrition;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of Standardized Uptake Value (SUV) | The variation of the SUVmax is defined as the difference of the tumoral SUV max between the TEP1 and the TEP2 | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
denutrition in Head and Neck cancer or oesophageal cancer
Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study

Study Overview
=================
Brief Summary
-----------------
Apathy has been reported to occur after subthalamic nucleus stimulation (STN-DBS), a treatment of motor complications in advanced Parkinson's disease (PD). It is not known whether postoperative apathy is related to dopamine withdrawal or a side effect of STN DBS. The researchers investigated potential predictors of apathy, and the effect of dopamine agonist treatment.

Official Title
-----------------
Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study

Conditions
-----------------
Apathy in Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parkinson disease Exclusion Criteria: Mattis scale < 130 Beck scale > 20

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
apathy, parkinson, agonist dopaminergic
Wearable Health Technology for Perioperative Risk Assessment

Study Overview
=================
Brief Summary
-----------------
Accurate and timely preoperative identification of high-risk patients provides opportunities to better inform and manage them. Current predictors for perioperative complications are either resource consuming or have low accuracy. The primary objective of the study is to assess if Wearable Devices may be an alternative to assess cardiopulmonary function, with low risks and lower costs.

Official Title
-----------------
Wearable Health Technology for Perioperative Risk Assessment

Conditions
-----------------
Surgery--Complications

Intervention / Treatment
-----------------
* Other: 6 Minute walking test
* Other: Frailty questionaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 70 or more Undergoing major non cardiac surgery Expected surgical duration > 2 hours. Exclusion Criteria: Patients unable to express consent Patients undergoing urgent/emergent surgery Patients in which surgery is planned within less than two weeks Patients with limited physical activity due to limited mobility related with neurological or orthopedic disease Acute cardiovascular event Surgery conducted in locoregional anesthesia only

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult patients undergoing major surgery<br>Patients aged 70 or older undergoing major non cardiac surgery, with expected surgical duration > 2 hours. | Other: 6 Minute walking test<br>* The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.<br>Other: Frailty questionaires<br>* Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess whether wearable devices (WD) can identify patients at risk for postoperative complications. |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare performance of WD data with 6MWT, MET scale, CFS and ASA score in identifying reduced functional capacity |  | 24 months | 
| A sub analysis of WD data during 6MWT will be conducted |  | 24 months |
Combination of Lymphatico-venular Anastomosis and Liposuction to Treat Cancer-related Lymphedema

Study Overview
=================
Brief Summary
-----------------
cooperation of an International team with many years of experience in surgical management of lymphedema description of an effective surgical strategy to treat cancer-related lymphedema, a high incidence pathology the combination of LVA and liposuction guarantees long lasting results

Detailed Description
-----------------
Cancer-related lymphedema represents one of the major complications of cancer treatment, especially for breast and gynecologic cancers. Moreover, it has high impact on cancer survivors and healthcare systems. Lymphedema management still remains challenging. The better understanding of lymphedema physiopathology as well as the development of sophisticated surgical and diagnostic techniques have led to effective strategies to address lymphedema patients but, despite the considerable interest in international literature, no consensus exist. The combination of LVA and liposuction may represent an effective strategy in treating patients with cancer-related lymphedema, in order to reach a significant decrease in volume and reduction of lymphangitis rate as well as stable results in time. In addition, it has the aim of being minimally invasive and well tolerated by patients

Official Title
-----------------
Combination of Lymphatico-venular Anastomosis and Liposuction to Treat Cancer-related Lymphedema: Rationale for a Regional Approach

Conditions
-----------------
Description of an Effective Surgical Strategy to Treat Cancer-related Lymphedema, Combination of LVA and Liposuction Guarantees Long Lasting Results

Intervention / Treatment
-----------------
* Procedure: combination of lymphaticovenular anastomosis and liposuction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients affected by secondary lymphedema free from cancer disease Exclusion Criteria: - persistence of the neoplastic pathology - patients affected by primary lymphedema

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group of partecipants<br>we combined two surgical techniques in the same group of patients | Procedure: combination of lymphaticovenular anastomosis and liposuction<br>* Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in volume | change in volume of the limb affected by cancer-related lymphedema | one year |
Ultrasound Guided Ureteroscopy and Ureteric Stones

Study Overview
=================
Brief Summary
-----------------
The prevalence of urolithiasis is steadily increasing with an estimation of 1 out of 11 people in the United States. The prevalence of calculi in Afro-Asian region including Arab Republic of Egypt ranges from 4% to 20%. Ureteroscopy is one of the first line treatments for definitive management of ureteric stones. Conventional ureteroscopy relies on intraoperative fluoroscopy for visualization and guidance, exposing the patient, surgeon and operating room staff to ionizing radiation. To minimize the hazards of ionizing radiation there has been a trend toward radiation free alternative imaging modalities . Ultrasound provides an excellent alternative for upper urinary tract imaging because it is radiation free, rapid, portable and allows excellent visualization of the renal pelvis and calyces. There is increasing awareness and concern about the clinical use of ionizing radiation and the need to decrease exposure of patients and medical professionals. Ultrasound guided ureteroscopy in pregnant females and children- in whom fluoroscopy is to be minimized or avoided when possible - has been reported.

Official Title
-----------------
Ultrasound Guided Ureteroscopy for the Treatment of Lower Third Ureteric Stones in Adults

Conditions
-----------------
Ureteric Stone

Intervention / Treatment
-----------------
* Procedure: ureteroscopy
* Radiation: Ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with single symptomatic lower third ureteric radio-opaque stones indicated for endoscopic treatment. Age group 18 years old or above. Stone size 15 mm or less. Exclusion Criteria: Patients with bilateral ureteric stones Ureteric congenital anomalies e.g. double ureter and ectopic ureter. Previously failed ureteroscopy or previous ureteroneocystostomy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Standardized ureteroscopy group<br> | Procedure: ureteroscopy<br>* The patients will be subjected to rigid ureteroscopy<br>|
| Other: Ultrasonography ureteroscopy group<br> | Procedure: ureteroscopy<br>* The patients will be subjected to rigid ureteroscopy<br>Radiation: Ultrasonography<br>* The patients will be subjected to Ultrasonography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients treated effectively by the two methods |  | 1 hour |
KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)

Study Overview
=================
Brief Summary
-----------------
KNOW-KT (KoreaN cohort study for Outcome in patients With KT: A 9-year Longitudinal cohort study of the Korean adult KT patients), funded by Korea Center for Disease Control and Prevention (KCDC) was established in 2012 by a group of transplant physicians, transplant surgeons, nephrologists, epidemiologists, and biostatisticians in Korea. We aimed to establish an adult KT cohort, to investigate the renal allograft outcomes, mortality, complications, and to explore traditional or nontraditional risk factors for morbidity and mortality. We established a bio-bank to integrate clinical and biological information. Here, we report design and method of the KNOW-KT.

Official Title
-----------------
KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation : A 9-year Longitudinal Cohort Study of the Kidney Transplantation (KNOW-KT)

Conditions
-----------------
Kidney Transplant Recipients, Complications After Kidney Transplant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recipients and Donors of kidney transplant Exclusion Criteria: Multi-organ transplant recipients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| KNOW-KT<br>1000 Kidney transplant recipients in Korea | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall mortality |  | 9 years | 
| Allograft survival | defined as re-transplant or initiation of maintenance dialysis | 9 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular event | Acute Myocardial Infarction Revascularization : PCI or CABG Stroke Admission from Congestive heart failure | 9 years | 
| Albuminuria |  | 9 years | 
| Acute Rejection |  | 9 years | 
| New onset of diabetes after transplant |  | 9 years | 
| Quality of Life |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
The cohort of Asian kidney transplant recipients, The cohort of metabolic complication after kidney transplant, The biorepository of Asian kidney transplant recipients
The Effect of Ulnar Nerve Entrapment Localization on Ipsilateral Upper Extremity Functions. The Effect of Ulnar Nerve Entrapment Localization on Ipsilateral Upper Extremity Functions. The Effect of Ulnar Nerve Entrapment Localization on Ipsilateral Upper Extremity Functions.

Study Overview
=================
Brief Summary
-----------------
Regardless of the cause of ulnar nerve entrapment neuropathy, investigators are planning to explore the relationship between the ipsilateral upper extremity dysfunction that may develop due to ulnar neuropathy and the level of entrapment in electromyelography.

Official Title
-----------------
The Effect of Ulnar Nerve Entrapment Localization on Ipsilateral Upper Extremity Functions in Patients With Ulnar Nerve Entrapment Neuropathy.

Conditions
-----------------
Ulnar Neuropathies

Intervention / Treatment
-----------------
* Diagnostic Test: EMG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: having ulnar nerve entrapment neuropathy with clinical examination and EMG (electroneuromyography) to be between the ages of 18-65 be give informed consent Exclusion Criteria: inflammatory arthritis hemiplegia contractures of shoulder-arm-hand joints

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Electromyelography<br>EMG will be performed only once to determine the ulnar nerve entrapment site in patients. | Diagnostic Test: EMG<br>* Electromyelography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disabilities of the Arm, Shoulder and Hand (DASH) score | Evaluation of upper extremity function between 0 and 100 points, higher scores mean a worse outcome. | 10 minutes. |